within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BB08_StaphylococcusImmunoglobulin;
model StaphylococcusImmunoglobulin 
   extends Pharmacolibrary.Drugs.ATC.J.J06BB08;

  annotation(Documentation(
    info ="<html><body><p>Staphylococcus immunoglobulin is a human plasma-derived immunoglobulin G preparation enriched with antibodies to Staphylococcus aureus. It has been used for the prophylaxis and treatment of severe staphylococcal infections, especially in high-risk patients such as neonates, immunocompromised individuals, or those with extensive burns. It is not in widespread approved use in current clinical practice, with most immunoglobulins today being non-specific or targeted to other pathogens.</p><h4>Pharmacokinetics</h4><p>There are no published peer-reviewed sources providing detailed pharmacokinetic parameters for staphylococcus immunoglobulin in either healthy volunteers or patient populations. The following values are estimated based on typical human intravenous immunoglobulin (IVIG) pharmacokinetics.</p><h4>References</h4><ol><li><p>Bateman, RM, et al., &amp; Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. <i>Critical care (London, England)</i> 20(Suppl 2) 94–None. DOI:<a href=&quot;https://doi.org/10.1186/s13054-016-1208-6&quot;>10.1186/s13054-016-1208-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27885969/&quot;>https://pubmed.ncbi.nlm.nih.gov/27885969</a></p></li><li><p>Tkaczyk, C, et al., &amp; Sellman, BR (2024). In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection. <i>Molecular therapy : the journal of the American Society of Gene Therapy</i> 32(8) 2505–2518. DOI:<a href=&quot;https://doi.org/10.1016/j.ymthe.2024.05.036&quot;>10.1016/j.ymthe.2024.05.036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38822525/&quot;>https://pubmed.ncbi.nlm.nih.gov/38822525</a></p></li><li><p>Deng, R, et al., &amp; Kamath, AV (2019). Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against . <i>mAbs</i> 11(6) 1162–1174. DOI:<a href=&quot;https://doi.org/10.1080/19420862.2019.1627152&quot;>10.1080/19420862.2019.1627152</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31219754/&quot;>https://pubmed.ncbi.nlm.nih.gov/31219754</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end StaphylococcusImmunoglobulin;
